Overview

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Status:
NOT_YET_RECRUITING

Trial end date:
2029-11-01

Target enrollment:

Participant gender:

Summary

This prospective clinical trial aims to investigate the impact of darolutamide in combination with standard-of-care androgen deprivation on physical activity, specifically step count, and its correlation with important markers of safety in vulnerable adults who screen positive by a brief geriatric assessment (GA) and metastatic hormone-sensitive prostate cancer.

Phase:

PHASE4

Details

Lead Sponsor:

University of Chicago

Treatments:

darolutamide
Hormones
Therapeutics